tiprankstipranks
Trending News
More News >
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY

Xspray Pharma AB (XSPRAY) AI Stock Analysis

Compare
1 Followers

Top Page

SE

Xspray Pharma AB

(Berlin:XSPRAY)

Rating:47Neutral
Price Target:
Xspray Pharma AB's stock score reflects significant financial challenges, particularly the lack of revenue and increasing debt levels, which weigh heavily on the overall assessment. While technical indicators show some positive momentum, they are not strong enough to offset the financial concerns. The stock's valuation, characterized by a negative P/E ratio, underscores the company's unprofitability. To improve the stock's attractiveness, achieving revenue generation and financial sustainability will be critical.

Xspray Pharma AB (XSPRAY) vs. iShares MSCI Sweden ETF (EWD)

Xspray Pharma AB Business Overview & Revenue Model

Company DescriptionXspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.
How the Company Makes MoneyXspray Pharma makes money by developing and commercializing improved versions of existing cancer drugs. The company's revenue model is based on licensing agreements and collaborations with larger pharmaceutical companies that have the resources and distribution networks to market the drugs. By using its HyNap technology, Xspray creates formulations that offer competitive advantages over original drugs, such as enhanced bioavailability and reduced side effects, making them attractive for licensing. Xspray typically earns upfront payments, milestone payments, and royalties from these partnerships. Additionally, the company may also generate revenue through direct sales if it chooses to commercialize certain products independently.

Xspray Pharma AB Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
1.06M0.000.000.000.000.00
Gross Profit
-1.64M-9.19M-9.53M-8.87M-1.41M-4.80M
EBIT
-285.71M-180.76M-133.07M-97.95M-53.46M-45.70M
EBITDA
-275.20M-169.81M-122.13M-87.82M-50.99M-40.90M
Net Income Common Stockholders
-285.52M-179.67M-130.27M-96.70M-52.30M-45.84M
Balance SheetCash, Cash Equivalents and Short-Term Investments
192.85M166.30M120.17M271.88M325.60M209.87M
Total Assets
307.38M765.26M585.43M622.90M605.30M400.67M
Total Debt
8.28M36.81M2.13M3.23M4.86M5.33M
Net Debt
-184.57M-129.50M-118.04M-268.65M-320.74M-204.54M
Total Liabilities
14.16M71.85M29.41M31.15M22.72M26.96M
Stockholders Equity
293.21M693.41M556.02M591.75M582.59M373.71M
Cash FlowFree Cash Flow
-264.51M-257.38M-238.47M-147.57M-145.00M-126.23M
Operating Cash Flow
-222.37M-203.28M-110.18M-51.61M-47.79M-34.24M
Investing Cash Flow
-42.14M-65.88M-135.34M-105.82M-96.83M-91.99M
Financing Cash Flow
306.11M315.59M93.81M103.71M260.35M114.84M

Xspray Pharma AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price32.00
Price Trends
50DMA
31.88
Positive
100DMA
31.82
Positive
200DMA
39.56
Negative
Market Momentum
MACD
-0.31
Negative
RSI
50.60
Neutral
STOCH
47.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Positive. The current price of 32 is above the 20-day moving average (MA) of 31.53, above the 50-day MA of 31.88, and below the 200-day MA of 39.56, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 50.60 is Neutral, neither overbought nor oversold. The STOCH value of 47.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XSPRAY.

Xspray Pharma AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
kr1.26B4.71152.78%1533.99%
54
Neutral
kr379.37M-47.73%45.52%93.35%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
48
Neutral
kr917.45M-48.22%67.70%
47
Neutral
kr1.19B-42.24%-19.44%
40
Neutral
kr367.75M-194.31%1643.36%50.36%
31
Underperform
€289.38M-167.55%46.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:XSPRAY
Xspray Pharma AB
32.00
-50.91
-61.40%
SE:CANTA
Cantargia AB
1.03
-3.48
-77.21%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.09
-6.76
-48.81%
SE:SANION
Saniona AB
9.45
6.28
198.11%
SE:XBRANE
Xbrane Biopharma AB
0.27
-0.04
-11.76%
SE:SYNACT
SynAct Pharma AB
16.84
9.90
142.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.